ROS1 and non-small cell lung carcinoma: In summary, for ROS1-positive patients with metastatic NSCLC, the priority first-line treatments encompass entrectinib, taletrectinib, or repotrectinib, with crizotinib, ceritinib, and lorlatinib as alternative options.